A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

The purpose of this study was to compare 2 weekly docetaxel‐based regimens as first‐line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to predict treatment‐related clinical outcomes.

[1]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[2]  J. Ajani,et al.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Cavalli,et al.  Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Van Cutsem,et al.  Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Lokich,et al.  Cutaneous Hand and Foot Toxicity Associated With Cancer Chemotherapy , 2003, American journal of clinical oncology.

[7]  K. Lee,et al.  Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer. , 2007, Cancer research and treatment : official journal of Korean Cancer Association.

[8]  R. James,et al.  Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Choi,et al.  Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer , 2005, American journal of clinical oncology.

[11]  C. Witton,et al.  Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER‐negative, but not ER‐positive, breast cancer , 2004, Histopathology.

[12]  M. Fujii.  Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study) , 2008, International Journal of Clinical Oncology.

[13]  M. Ringuette,et al.  Interaction between SPARC and tubulin in Xenopus , 2004, Cell and Tissue Research.

[14]  H. K. Kim,et al.  Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma , 2008, British Journal of Cancer.

[15]  L. Hiller,et al.  Review of second-line chemotherapy for advanced gastric adenocarcinoma. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S Hsueh,et al.  Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance , 2004, British Journal of Cancer.

[18]  D. Burstein,et al.  Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. , 2008, Annals of diagnostic pathology.

[19]  Sukjoong Oh,et al.  Phase II study of S‐1 and irinotecan combination chemotherapy as a first‐line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05‐02 , 2009 .

[20]  H. Narahara,et al.  Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer , 2006, British Journal of Cancer.

[21]  J. Lea,et al.  Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. , 2009, American journal of obstetrics and gynecology.

[22]  K. Rufibach,et al.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Z. Ye,et al.  SPARC Is Associated with Gastric Cancer Progression and Poor Survival of Patients , 2009, Clinical Cancer Research.

[24]  M. J. van den Bent,et al.  Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Sage,et al.  The Copper Binding Domain of SPARC Mediates Cell Survival in Vitro via Interaction with Integrin β1 and Activation of Integrin-linked Kinase* , 2008, Journal of Biological Chemistry.

[26]  H. Chung,et al.  Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. , 2007, The oncologist.

[27]  Kazuhiro Yoshida,et al.  Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer , 2006, Clinical Cancer Research.

[28]  Kazuhiro Yoshida,et al.  Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell lines , 2006, International journal of cancer.

[29]  Hong Wang,et al.  A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas , 2010, Oncology.

[30]  M. Fukushima,et al.  Increased Antitumor Activity in Combined Treatment TS-1 and Docetaxel , 2005, Oncology.

[31]  T. Kubota,et al.  Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism , 2004, Cancer science.